Search
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalNintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). … nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to
Novobiocin
go.drugbank.com/drugs/DB01051ApprovedInvestigationalVet approvedWithdrawnIt has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. … Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious infections due to
Synonyms: N-{7-[(3-O-carbamoyl-6-deoxy-5-methyl-4-O-methyl-β-D-gulopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl}-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamideMolybdenum
go.drugbank.com/drugs/DB11137ApprovedInvestigationalMolybdenum is a chemical element with symbol Mo and atomic number 42. As it is not a naturally occuring free metal on Earth, molybdenum is found only in various oxidation states in minerals.
Mixtures: ADDAMEL N, Protect Plus SO 60Asenapine
go.drugbank.com/drugs/DB06216ApprovedInvestigationalDeveloped by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with … Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSutilain
go.drugbank.com/drugs/DB09379ApprovedWithdrawn[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … It is able to dissolve the intercellular matrix which helps with desquamation.
Vepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508, A275509] On May 1, 2026, the FDA granted approval for vepdegestrant tablets under the trade name VEPPANU. … [A275507, A275509] It serves as an advanced option to address the clinical challenge of endocrine-resistant breast cancer subtypes.
Baricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
Mangafodipir
go.drugbank.com/drugs/DB06796ApprovedInvestigationalWithdrawnTeslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012. … Enhanced contrast by mangafodipir improves visualization and detection of lesions of the liver formed from metastatic disease or hepatocellular carcinomas.
Inositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnIt is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate. … Inositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator.
Betibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigational[L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … The use of betibeglogene autotemcel is more effective in patients with β-thalassemia with residual β-globin synthesis (non-β<sup>0</sup>/β<sup>0</sup> genotype) compared to those with no detectable β-globin